Biocon Limited (NSE: BIOCON) announced that its Pertuzumab biosimilar has become the first biosimilar to secure a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval recommendation under the new tailored clinical approach marks a significant milestone for Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited. The biosimilar, marketed under the brand name Pebrilzo®, is indicated for the treatment of HER2-positive breast cancer across multiple disease stages.

Extensive Clinical and Analytical Validation

The positive CHMP opinion follows a comprehensive review of the marketing authorization application submitted by Biocon Biologics Ireland Limited. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Pebrilzo® is highly similar to the reference biologic, with no clinically meaningful differences in quality, safety, or efficacy.

Expanding Access to Biologic Therapies

Shreehas Tambe, CEO & Managing Director of Biocon, said: “The positive CHMP opinion for our Pertuzumab biosimilar marks an important step toward expanding access to biologic therapies for patients with HER2-positive breast cancer in Europe.” This approval reflects an important milestone in the evolution of biosimilar science and greater regulatory confidence on advanced analytical and clinical pharmacology evidence to establish biosimilarity.

As the first monoclonal antibody biosimilar to receive a positive CHMP opinion under EMA’s tailored clinical development approach, this approval is a testament to Biocon’s commitment to providing affordable, life-changing medicines to patients worldwide.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 44% of its 52-week range with RSI at 35. In other words, neither side has a clear edge right now. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Laurus Labs Limited (NSE: LAURUSLABS) has announced its financial results for FY26, showcasing a robust performance with a 23% increase in revenue to ₹6,813 crore. The company’s EBITDA margin stood at 26.8%, reflecting its strong operational efficiency and strategic growth initiatives. The company’s total capital expenditure for FY26 was ₹1,826 crore, marking a 64% year-over-year increase. Looking ahead, Laurus Labs is guiding for an EBITDA margin of over 30% starting FY27, driven by accelerated capital expenditures and strategic investments in its manufacturing and technology platforms.

Operational Highlights

Laurus Labs has demonstrated a consistent track record in multi-site manufacturing capabilities, with a focus on quality, regulatory compliance, and innovation. The company’s manufacturing network spans 15 sites globally, including new and expanding facilities in Visakhapatnam and Hyderabad. The company has invested over ₹4,300 crore in building a diversified portfolio across various technologies, including API, formulations, peptides, fermentation, gene therapy, and antibody drug conjugates.

Future Growth Prospects

With a healthy order book and a strong internal pipeline, Laurus Labs is well-positioned to meet growing customer demands. The company plans to continue its accelerated capital expenditure, targeting over ₹3,000 crore in FY27 and FY28 to further strengthen its manufacturing network and technological capabilities. As a result, the company expects to achieve a higher asset turnover ratio, aligning with its long-term growth strategy.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Laurus Labs Limited

Laurus Labs Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Laurus gains 38.3% over three months and trades near its 52-week highs. The PEG stands at 24.10 — severely stretched. Any earnings miss could trigger a sharp de-rating. No meaningful dividend — total return is entirely dependent on capital appreciation. Sellers drive 2.2x the volume of buyers. Furthermore, they controlled 11 of recent sessions versus 19 for buyers — a clear distribution signal. Revenue grows at 3.8% CAGR and the PEG stands at 24.10. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of Laurus Labs Limited.

Fabtech Technologies Limited, a global provider of integrated design, engineering and build solutions for regulated manufacturing environments, has secured a INR 21 crore turnkey project in a CIS country. The order marks Fabtech’s entry into this CIS market and expands the Company’s international execution footprint into a technically demanding geography.

Project Scope

The project involves the development of critical internal infrastructure for an advanced medical-device manufacturing facility. Fabtech’s scope includes integrated engineering and design, cleanroom systems, HVAC, building management systems, electrical systems, process and clean utilities, laboratory and cleanroom furniture, fire and life-safety systems, installation, testing and commissioning.

Strategic Impact

Strategically, the order opens a new geography for Fabtech while demonstrating the portability of its integrated Design-Engineer-Build model across markets with materially different climatic, regulatory and infrastructure conditions. The entry into this CIS country further strengthens Fabtech’s growing international business and its positioning as a single-point partner for complex, regulated manufacturing infrastructure.

Mr. Aman Anavkar, Chief Growth Officer, Fabtech Technologies Limited, said: “Entering CIS country through a project of this technical complexity is an important milestone for Fabtech. The mandate is not simply to supply infrastructure, but to engineer a manufacturing environment around the process, the local climate and the customer’s long-term operating requirements. Bringing design, utilities, cleanroom systems, HVAC, electrical integration and validation thinking under one execution framework is central to the value we bring to this project.”

As pharmaceutical manufacturing capacity expands across emerging markets, Fabtech Technologies remains focused on leveraging its engineering expertise, international presence and execution capabilities to participate in the next phase of global healthcare infrastructure development.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fabtech Technologies Limited

Fabtech Technologies Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.

Fabtech trades in the lower quarter of its 52-week range. The PEG of 0.64 signals undervaluation relative to growth. It is a potential re-rating candidate. Revenue grows at 28.3% and profits at 20.8% CAGR. Both numbers are exceptional. The stock sits at 10% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 28.3% and profits at 20.8% CAGR — a genuinely strong business. Nevertheless, the stock drops 7.1% in three months. The market sells the stock, not the story. Watch whether that changes at the next earnings. Check Fundamentals of Fabtech Technologies Limited.